Browse Category

Stock Market News 23 December 2025

Procter & Gamble Stock (NYSE: PG) Today: What’s Driving Shares on Dec. 23, 2025 — Analyst Targets, Earnings Outlook, and Key Risks

Procter & Gamble Stock (NYSE: PG) Today: What’s Driving Shares on Dec. 23, 2025 — Analyst Targets, Earnings Outlook, and Key Risks

Procter & Gamble (The Procter & Gamble Company, ticker PG) is closing out 2025 with its stock hovering near the lower half of its 52-week range—an area that’s attracting fresh attention from analysts and long-term dividend investors alike. As of
Visa Stock News Today (Dec. 23, 2025): Holiday Spending Data, Stablecoin Settlement Push, and Wall Street Forecasts for V

Visa Stock News Today (Dec. 23, 2025): Holiday Spending Data, Stablecoin Settlement Push, and Wall Street Forecasts for V

Visa Inc. (NYSE: V) stock is back in the spotlight on Dec. 23, 2025, as fresh holiday spending data adds new color to the consumer-demand picture—and as investors weigh the payments giant’s fast-moving strategy in stablecoin settlement and AI-driven “agentic
ZIM Integrated Shipping (ZIM) Stock Surges on Competing Buyout Proposals: Latest News, Analyst Targets, Dividend, and 2026 Shipping Outlook

ZIM Integrated Shipping (ZIM) Stock Surges on Competing Buyout Proposals: Latest News, Analyst Targets, Dividend, and 2026 Shipping Outlook

December 23, 2025 — Shares of ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) jumped Tuesday after the company disclosed that its board has received multiple competing proposals to acquire the company’s outstanding shares, escalating a strategic review that has been
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven
Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck & Co., Inc. (NYSE: MRK) is closing in on year-end with a rare mix of policy-driven headlines, regulatory acceleration, and pipeline catalysts that are shaping investor expectations for 2026 and beyond. From a White House-backed drug-pricing framework that offers
Bank of America Stock (NYSE: BAC) News Today: Fed Rate Cuts, Analyst Price Targets, and What Investors Are Watching on Dec. 23, 2025Bank of AmericaBank of America Stock (NYSE: BAC) News Today: Fed Rate Cuts, Analyst Price Targets, and What Investors Are Watching on Dec. 23, 2025

Bank of America Stock (NYSE: BAC) News Today: Fed Rate Cuts, Analyst Price Targets, and What Investors Are Watching on Dec. 23, 2025Bank of AmericaBank of America Stock (NYSE: BAC) News Today: Fed Rate Cuts, Analyst Price Targets, and What Investors Are Watching on Dec. 23, 2025

Bank of America Corporation (NYSE: BAC) stock is trading near its recent highs as 2025 winds down, with investors balancing three big forces: a shifting interest-rate outlook, improving Wall Street deal momentum, and a growing stack of analyst upgrades heading
Lionsgate Studios Corp (NYSE: LION) Stock Jumps to New Highs on Dec. 23, 2025: Latest News, Analyst Forecasts, and What’s Driving the Move

Lionsgate Studios Corp (NYSE: LION) Stock Jumps to New Highs on Dec. 23, 2025: Latest News, Analyst Forecasts, and What’s Driving the Move

December 23, 2025 — Lionsgate Studios Corp stock is having a loud day in the market. Shares of Lionsgate Studios Corp (NYSE: LION) traded around $9.06 Tuesday, up roughly 8%–9%, after touching an intraday high near $9.23 (and a low
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

December 23, 2025 — Eli Lilly and Company stock (NYSE: LLY) is holding near record territory as investors digest a fresh twist in the weight-loss drug race: the FDA has cleared Novo Nordisk’s first oral version of Wegovy, intensifying competition
1 124 125 126 127 128 962
Go toTop